Lovelace Scientific

Executive Summary

Lovelace Biomedical, operating as Lovelace Scientific, is a longstanding not-for-profit preclinical contract research organization (CRO) based in Albuquerque, New Mexico. Since its founding in 1947, it has specialized in toxicology, pharmacology, and disease characterization, with particular expertise in respiratory, infectious disease, and gene therapy research. The organization operates a large, bio-secure facility equipped for high-containment work, enabling it to serve as a critical partner for pharmaceutical and biotech companies in advancing drug candidates through preclinical stages. Despite being a CRO rather than a drug developer, Lovelace's deep domain knowledge and specialized infrastructure position it well to capitalize on growing demand for outsourced preclinical services, especially in areas like gene therapy and infectious disease. The organization's not-for-profit model and focus on collaborative partnerships further enhance its reputation and ability to attract contracts from both commercial and government sponsors.

Upcoming Catalysts (preview)

• Q3 2026New contract win with a major gene therapy developer70% success
• Q4 2026Expansion of high-containment facility to handle BSL-4 pathogens30% success
• Q2 2026Receipt of federal grant for infectious disease research60% success